Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection

Table 1 Microbiologic and pathologic findings following anti-RAGE mAb therapy in cecal ligation and puncture

Parameter	Sham	Serum control	Anti-RAGE mAb (15 mg/kg)
Number of mice	5	15	15
Aerobic Gram-negative bacteria (CFU/g)	0.6 ± 1.5^a	5,643 ± 1,281	4,910 ± 395
Aerobic Gram-positive bacteria (CFU/g)	601 ± 548^a	15,616 ± 6,800	11,222 ± 1,873
Pathology score (lung, small bowel)	0.6 ± 0.5	3.0 ± 0.9^b	1.8 ± 1.1
Wet-to-dry ratio (lung tissue)	4.6 ± 0.6	5.3 ± 0.5	5.1 ± 0.6

^aP < 0.05 sham versus other groups; ^bP < 0.005 control versus sham or anti-RAGE mAb. CFU, colony-forming units; mAb, monoclonal antibody; RAGE, receptor for advanced glycation end products.

ISSN: 1364-8535